MAP2K7 and melanoma: A phase 1b/2 study of tovorafenib monotherapy and combination of tovorafenib plus MEK inhibitor pimasertib in patients with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the mitogen-activated protein kinase (MAPK) pathway (FIRELIGHT; NCT04985604) 20 and a phase 3 study of tovorafenib monotherapy versus SOC chemotherapy in patients with pediatric low-grade glioma harboring an activating RAF alteration who require first-line systemic therapy (LOGGIC/FIREFLY-2; NCT05566795) are ongoing 21.